DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
Abstract
Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification of biomarkers distinguishing responders and nonresponders will improve management of patients with cancer. Because the DC-HIL checkpoint differs from the PD1 pathway in expression and inhibitory mechanisms, we examined whether DC-HIL expression regulates ICI responsiveness.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 13, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2360
Entities
People
- David E. Gerber
- Farjana Fattah
- Jin-sung Chung
- Kiyoshi Ariizumi
- Masato Kobayashi
- Ponciano D. Cruz Jr
- Song Zhang
- Vijay Ramani
- Vinita Popat
Organizations
- American Cancer Society
- United States Department of Defense
- University of Texas Southwestern Medical Center